NEJM publishes full analysis of Rydapt® (midostaurin) Phase III RATIFY trial in newly diagnosed FLT3-mutated acute myeloid leukemia (AML)

Novartis International AG / NEJM publishes full analysis of Rydapt® (midostaurin) Phase III RATIFY trial in newly diagnosed FLT3-mutated acute myeloid leukemia (AML) . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement...

London, 23/06/2017 (informazione.it - comunicati stampa - salute e benessere)